Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial. (Q46489542)

From Wikidata

Jump to navigation Jump to search

scientific article published in August 2008

Language	Label	Description	Also known as
English	Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.	scientific article published in August 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

peritoneal carcinomatosis

1 reference

based on heuristic

inferred from title

author name string

Robert E Emerson

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Nancy Menning

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Lee Ann Baldridge

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Cynthia S Johnson

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Tim Breen

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

John McClean

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Doyle Stephens

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Charles Whalen

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Gregory Sutton

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

language of work or name

0 references

publication date

1 August 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

113

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

723-732

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18618737%20AND%20SRC:MED&resulttype=core&format=json

10 January 2020

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Two classes of PDGF receptor recognize different isoforms of PDGF

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

PDGF alpha- and beta-receptors activate unique and common signal transduction pathways

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression in epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene expression signature with independent prognostic significance in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

PDGF BB induces VEGF secretion in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23605

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46489542&oldid=1587191132"